Cover Image
市場調查報告書

西尼羅病毒感染疾病:開發中產品分析

West Nile Virus Infections - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 201011
出版日期 內容資訊 英文 71 Pages
訂單完成後即時交付
價格
Back to Top
西尼羅病毒感染疾病:開發中產品分析 West Nile Virus Infections - Pipeline Review, H2 2016
出版日期: 2016年09月21日 內容資訊: 英文 71 Pages
簡介

西尼羅病毒感染疾病,是由蚊子傳播的病毒所引起。西尼羅病毒,又稱黃病毒,是病毒的一種。

本報告提供西尼羅病毒感染疾病的治療藥的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

西尼羅病毒感染疾病概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

西尼羅病毒感染疾病:企業開發中的治療藥

西尼羅病毒感染疾病:大學/機關研究中的治療藥

西尼羅病毒感染疾病:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

西尼羅病毒感染疾病:企業開發中的產品

西尼羅病毒感染疾病:大學/機關研究中的產品

西尼羅病毒感染疾病的治療藥的開發企業

  • BioDiem Ltd
  • CalAsia Pharmaceuticals, Inc.
  • CEL-SCI Corporation
  • Kineta, Inc.
  • Nanotherapeutics, Inc.

西尼羅病毒感染疾病:治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

西尼羅病毒感染疾病:最近的開發平台趨勢

西尼羅病毒感染疾病:暫停中的計劃

西尼羅病毒感染疾病:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8483IDB

Summary

Global Markets Direct's, 'West Nile Virus Infections - Pipeline Review, H2 2016', provides an overview of the West Nile Virus Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for West Nile Virus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for West Nile Virus Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of West Nile Virus Infections
  • The report reviews pipeline therapeutics for West Nile Virus Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved West Nile Virus Infections therapeutics and enlists all their major and minor projects
  • The report assesses West Nile Virus Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for West Nile Virus Infections

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for West Nile Virus Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding West Nile Virus Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • West Nile Virus Infections Overview
  • Therapeutics Development
    • Pipeline Products for West Nile Virus Infections - Overview
    • Pipeline Products for West Nile Virus Infections - Comparative Analysis
  • West Nile Virus Infections - Therapeutics under Development by Companies
  • West Nile Virus Infections - Therapeutics under Investigation by Universities/Institutes
  • West Nile Virus Infections - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • West Nile Virus Infections - Products under Development by Companies
  • West Nile Virus Infections - Products under Investigation by Universities/Institutes
  • West Nile Virus Infections - Companies Involved in Therapeutics Development
    • CEL-SCI Corporation
    • Hemispherx Biopharma, Inc.
    • Kineta, Inc.
    • Nanotherapeutics, Inc.
    • Plex Pharmaceuticals, Inc.
  • West Nile Virus Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Alferon LDO - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BG-323 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CEL-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FDX-000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HydroVax-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon alfa-n3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KIN-1148 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KIN-1400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for West Nile Virus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rintatolimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RL-15A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit NS2B-NS3 Protease for Dengue, Zika and West Nile Virus Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit NS3 Protease for Dengue and West Nile Virus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide for Dengue Virus and West Nile Virus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Tatbeclin-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • West Nile virus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • West Nile virus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • West Nile Virus Infections - Dormant Projects
  • West Nile Virus Infections - Product Development Milestones
    • Featured News & Press Releases
      • Jul 06, 2015: NIH-funded vaccine for West Nile Virus enters human clinical trials
      • May 05, 2014: Alferon N Effective Against MERS Virus In-Vitro
      • Sep 12, 2013: Hemispherx Announces Initial Test Results in Biosecurity/Biodefense Arena
      • Sep 06, 2011: Hemispherx Enters Into Strategic Alliance With Armada Health Care For Alferon N Injection
      • Apr 20, 2010: Kineta Scientist to Present Novel Antiviral Research Findings at International Conference
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for West Nile Virus Infections, H2 2016
  • Number of Products under Development for West Nile Virus Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • West Nile Virus Infections - Pipeline by CEL-SCI Corporation, H2 2016
  • West Nile Virus Infections - Pipeline by Hemispherx Biopharma, Inc., H2 2016
  • West Nile Virus Infections - Pipeline by Kineta, Inc., H2 2016
  • West Nile Virus Infections - Pipeline by Nanotherapeutics, Inc., H2 2016
  • West Nile Virus Infections - Pipeline by Plex Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • West Nile Virus Infections - Dormant Projects, H2 2016
  • West Nile Virus Infections - Dormant Projects (Contd..1), H2 2016
  • West Nile Virus Infections - Dormant Projects (Contd..2), H2 2016

List of Figures

  • Number of Products under Development for West Nile Virus Infections, H2 2016
  • Number of Products under Development for West Nile Virus Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top